The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and ...

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) has achieved a significant milestone with the FDA's recent approval of Cobenfy ...

The National Medical Products Administration (NMPA) in China has granted approval for Dupixent® (dupilumab) as an add-on maintenance treatment for adults suffering from uncontrolled chronic ...

Upstream Bio plans to IPO to advance its Phase 2 drug candidate, verekitug, for severe asthma and chronic rhinosinusitis.

COPD and BPD: Inhalation of Live Lactobacilli Lessens Lung Inflammation and Improves Lung Function Aug. 21, 2024 — In preclinical models, the inhalation of a mixture of living Lactobacilli ...

Global Portable Oxygen Concentrators Market is valued approximately at USD 2.45 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 10.03% over the forecast period ...

Global Home Respiratory Therapy Market is valued at approximately USD 8.55 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 6.72% over the forecast period 2024-2032.

The drug targets patients who experience exacerbations despite traditional triple therapy (LABA, LAMA, ICS), addressing an unmet need in COPD treatment. Verona's financial position is stable ...

We use all three to treat chronic obstructive pulmonary disease (COPD). When and how to use one ... statement provides flow charts with a tidy grading system that uses capital letters.

Mepolizumab was found to significantly reduce exacerbations in adults with chronic obstructive pulmonary disease (COPD), according to results from the MATINEE trial ... Moderate exacerbations were ...

The extent of skin involvement and the severity of symptoms determine the stage, which helps guide the choice of treatment. Moderate psoriasis affects about 3% to 10% of the body surface and ...

Overall, the pathogenesis and treatment of PRISm have significant knowledge gaps, according to the committee. “Not all individuals with pre-COPD or PRISm will eventually develop fixed airflow ...